Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

116.70EUR
26 May 2017
Change (% chg)

€-0.05 (-0.04%)
Prev Close
€116.75
Open
€116.85
Day's High
€117.00
Day's Low
€116.30
Volume
1,425,565
Avg. Vol
1,901,684
52-wk High
€118.40
52-wk Low
€85.00

Latest Key Developments (Source: Significant Developments)

Evotec receives milestone as part of alliance with Bayer
Monday, 22 May 2017 01:29am EDT 

May 22 (Reuters) - Evotec AG :Evotec receives pre-clinical milestone as part of its endometriosis alliance with Bayer.Payment of approx. Eur 5 m to Evotec for transition of a programme into pre-clinical development for treatment of endometriosis.This milestone was achieved under successful strategic alliance between Evotec and Bayer entered in october 2012.  Full Article

FDA grants Bayer priority review for investigational compound Copanlisib
Wednesday, 17 May 2017 02:30am EDT 

May 17 (Reuters) - Bayer Ag :FDA grants Bayer priority review for investigational compound Copanlisib in Follicular Lymphoma.U.S. Food and drug administration has granted priority review designation for new drug application for Copanlisib.  Full Article

FDA grants priority review to Bayer anti-cancer compound
Wednesday, 17 May 2017 02:00am EDT 

May 17 (Reuters) - Bayer AG :Says receives FDA priority review for investigational anti-cancer compound copanlisib.  Full Article

Bayer still sees competition after Monsanto takeover
Friday, 28 Apr 2017 10:15am EDT 

April 28 (Reuters) - Bayer AG CEO at AGM:Says assumes that there will still be considerable competition even after Monsanto <<>> deal is completed.  Full Article

Monsanto deal hasn't affected Bayer business - Bayer CEO
Friday, 28 Apr 2017 09:21am EDT 

April 28 (Reuters) - Bayer AG CEO at AGM:Says Monsanto takeover has so far not had any visible effect on the development of our business.  Full Article

U.S. FDA expands approved use of Stivarga to treat liver cancer
Thursday, 27 Apr 2017 12:54pm EDT 

April 27 (Reuters) - U.S. FDA::FDA expands approved use of Stivarga to treat liver cancer.The FDA granted the approval of Stivarga to Bayer Healthcare Pharmaceuticals Inc.  Full Article

Crispr Therapeutics, Casebia Therapeutics announce exclusive development and option agreement with Stridebio
Monday, 17 Apr 2017 08:00am EDT 

April 17 (Reuters) - Crispr Therapeutics Ag :Crispr Therapeutics and Casebia Therapeutics announce exclusive development and option agreement with Stridebio.Crispr Therapeutics - under agreement, Stridebio will use proprietary platform to develop AAV vectors with improved properties.Crispr Therapeutics - co, Casebia will have option to exclusively license aav vectors with desired properties for use in their in Vivo gene-editing programs.Stridebio will receive development funding, milestones and royalties on licensed vectors.Stridebio will retain certain rights to use Novel aav vectors for gene therapy applications.  Full Article

Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept
Monday, 10 Apr 2017 08:02am EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept . Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons . Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics . Oncomed Pharmaceuticals Inc - small molecule program under companies' collaboration continues without change .Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept.  Full Article

Monsanto Q2 earnings per share $3.09
Wednesday, 5 Apr 2017 08:00am EDT 

Monsanto Co : Monsanto continues return to growth in fiscal year 2017 with strong second quarter and first half results; updates outlook for full year eps to high end of guidance range . Q4 sales $5.1 billion versus $4.5 billion . Q2 earnings per share $3.19 from continuing operations . Q2 earnings per share $3.09 . Q2 earnings per share view $2.82 -- Thomson Reuters I/B/E/S . Monsanto - full year 2017 eps guidance now expected to be at high end of range of $3.95 to $4.44 on an as-reported basis and $4.50 to $4.90 on an ongoing basis . Monsanto Co - "continue to expect growth in global corn platform, led by price increases in local currency in south america" . Monsanto Co says for Q3, expects as-reported earnings per share to be roughly flat due to absence of argentine-related tax matters call-out of $0.50 /share . Fy2017 earnings per share view $4.75 -- Thomson Reuters I/B/E/S . Monsanto Co - qtrly total seeds and genomics sales $4,186 million versus $3,817 million . Monsanto Co says continues to expect seed and genomics segment gross profit to increase mid-single digits as a percent year-over-year in 2017 . Monsanto Co says within its AG productivity segment, gross profit is still expected to be in range of $850 to $950 million in 2017 . Monsanto-Overall operating expenses in 2017, excluding pending bayer deal-related costs & restructuring charges, expected to increase slightly.  Full Article

Crispr and Casebia announce commercial license agreement with Maxcyte
Tuesday, 14 Mar 2017 07:00am EDT 

Crispr Therapeutics Ag : Crispr Therapeutics and Casebia Therapeutics announce commercial license agreement with Maxcyte . Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments . Says commercial license builds on an existing research and clinical licensing agreement for select disease areas .Crispr, Casebia will obtain non-exclusive commercial-use rights to Maxcyte's cell engineering platform to develop crispr/CAS9-based therapies for SCID.  Full Article

More From Around the Web

Bayer, J&J to face second trial over Xarelto bleeding risks

Bayer AG and Johnson & Johnson are set to return to a New Orleans federal courthouse on Tuesday with a goal of scoring their second trial win amid thousands of lawsuits blaming injuries on the blood thinner Xarelto.